English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We appreciate the discussion initiated by Badrick et al. (1) and thank them for the questions raised. In an ideal world, we would have a randomized trial with the enormous sample necessary to answer this question as well as decades of follow-up. In an imperfect world, our analysis reveals the experience of a significant fraction of U.S. patients with diabetes using insulin glargine over 3 years of observation.Regarding our prevalent users cohort and fixed treatment group assignment, we acknowledged the reasonable but unproven assumption that our observed exposure reflects unobserved exposure, preceding 2006 (Part D inception). Under this assumption, assignment to treatment observed in the earliest observation window is the best exposure …

diabetes care

Response to Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients. Diabetes Care 2011;34:1965-1971